Incannex Healthcare (NASDAQ:IXHL) Downgraded by Zacks Research to “Strong Sell”

Posted by Amy Steele on Oct 8th, 2026

Zacks Research downgraded shares of Incannex Healthcare (NASDAQ:IXHL – Free Report) from a hold rating to a strong sell rating in a research note published on Tuesday morning,Zacks reports.

IXHL has been the topic of a number of other reports. Alliance Global Partners initiated coverage on Incannex Healthcare in a report on Monday, June 8th. They issued a “buy” rating and a $18.00 price objective on the stock. Wall Street Zen cut Incannex Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, October 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Incannex Healthcare in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Incannex Healthcare has an average rating of “Reduce” and a consensus target price of $18.00.

View Our Latest Research Report on Incannex Healthcare

Incannex Healthcare Stock Performance

Incannex Healthcare stock opened at $3.18 on Tuesday. Incannex Healthcare has a 1 year low of $2.49 and a 1 year high of $14.91. The firm has a 50 day moving average price of $3.32 and a 200 day moving average price of $3.44. The company has a market cap of $39.91 million, a price-to-earnings ratio of -1.88 and a beta of 6.97.

Incannex Healthcare (NASDAQ:IXHL – Get Free Report) last announced its quarterly earnings results on Friday, September 25th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.27). Sell-side analysts predict that Incannex Healthcare will post -2.63 EPS for the current year.

Incannex Healthcare Company Profile

(Get Free Report)

Incannex Healthcare Limited is an Australia-based clinical-stage pharmaceutical company developing therapies for conditions with significant unmet medical needs. The company’s research programs focus on cannabinoid-based medicines and psychedelic-assisted psychotherapy, with development activities spanning sleep disorders, respiratory and inflammatory diseases, pain, and mental health.

Its pipeline includes IHL-42X, an investigational combination of dronabinol and acetazolamide being developed for obstructive sleep apnea.